Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Pui

Showing results (321-330 of 414) with videos related to

Pageof 42
Sort By:
Cancer Research|August 1, 1984
Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemiaC H Pui, R J Aur, W P Bowman, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemiaN Pottier, S W Paugh, C Ding, et al.
Haematology and Blood Transfusion|January 1, 1985
Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk featuresS B Murphy, G V Dahl, A T Look, et al.
Clinical Pharmacology and Therapeutics|January 29, 2011
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingM V Relling, E E Gardner, W J Sandborn, et al.
Blood|May 1, 1995
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemiaT Okuda, S A Shurtleff, M B Valentine, et al.
Lancet (London, England)|January 22, 1991
Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyG K Rivera, S C Raimondi, M L Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and XC H Pui, R K Dodge, A T Look, et al.
Leukemia|February 1, 1992
Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study XC H Pui, J V Simone, M L Hancock, et al.
Leukemia|December 1, 1995
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosisS A Shurtleff, A Buijs, F G Behm, et al.
Leukemia|October 3, 2002
Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experienceJ E Rubnitz, S C Raimondi, A R Halbert, et al.
Pageof 42

Showing results (321-330 of 414) with videos related to

Sort By:
Pageof 42
Cancer Research|August 1, 1984
Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemiaC H Pui, R J Aur, W P Bowman, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemiaN Pottier, S W Paugh, C Ding, et al.
Haematology and Blood Transfusion|January 1, 1985
Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk featuresS B Murphy, G V Dahl, A T Look, et al.
Clinical Pharmacology and Therapeutics|January 29, 2011
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingM V Relling, E E Gardner, W J Sandborn, et al.
Blood|May 1, 1995
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemiaT Okuda, S A Shurtleff, M B Valentine, et al.
Lancet (London, England)|January 22, 1991
Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyG K Rivera, S C Raimondi, M L Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and XC H Pui, R K Dodge, A T Look, et al.
Leukemia|February 1, 1992
Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study XC H Pui, J V Simone, M L Hancock, et al.
Leukemia|December 1, 1995
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosisS A Shurtleff, A Buijs, F G Behm, et al.
Leukemia|October 3, 2002
Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experienceJ E Rubnitz, S C Raimondi, A R Halbert, et al.
Pageof 42